Quick Answer
Ernexa Therapeutics Inc. reported Total Revenue of $582.0 thousand for fiscal year 2024.
Ernexa Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $582.0K +755.9% |
$68.0K | $0.00 | — | $5.80M -70.7% |
| Revenue (ASC 606) | — | — | — | — | — | $5.80M -70.7% |
| Net Income | -$14.08M +68.4% |
-$44.54M -105.6% |
-$21.67M +11.8% |
-$24.58M +79.9% |
-$122.55M -361.9% |
-$26.53M -1196.1% |
| Diluted EPS | -$2.24 +95.4% |
-$48.96 -1100.0% |
-$4.08 +49.4% |
-$8.06 +85.8% |
-$56.61 -3649.0% |
-$1.51 |
| Total Assets | $5.83M +10.7% |
$5.27M -89.3% |
$49.13M +120.5% |
$22.28M -29.3% |
$31.52M +128.8% |
$13.78M -2.5% |
| Cash and Equivalents | — | $1.73M -77.2% |
$7.58M -33.8% |
$11.45M -32.6% |
$16.98M +2086.0% |
$777.0K -75.8% |
| Long-Term Debt | — | — | — | — | — | $532.0K |
| Stockholders Equity | $2.40M +41.2% |
$1.70M -23.8% |
$2.23M -81.6% |
$12.11M -52.5% |
$25.50M +233.0% |
$7.66M -21.4% |
| Operating Income | -$9.32M +40.5% |
-$15.67M +25.8% |
-$21.14M +36.4% |
-$33.22M +70.8% |
-$113.73M -329.4% |
-$26.49M -1403.3% |
| Gross Profit | — | $486.0K +389.3% |
-$168.0K | $0.00 | — | — |
| Shares Outstanding | 7.85M -84.7% |
51.39M +849.8% |
5.41M +5.5% |
5.13M +97.1% |
2.60M | 0 -100.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $487.0K | +854.9% | +936.2% |
| Revenue (ASC 606) | September 30, 2020 | $1.48M | -67.8% | +95.9% |
| Net Income | September 30, 2025 | -$1.24M | +95.3% | +60.5% |
| Diluted EPS | September 30, 2025 | -$0.15 | +99.8% | +75.4% |
| Total Assets | September 30, 2025 | $6.17M | -20.0% | -18.6% |
| Cash and Equivalents | June 30, 2025 | $4.32M | +66.9% | +125.0% |
| Long-Term Debt | September 30, 2020 | $1.62M | — | +0.0% |
| Stockholders Equity | September 30, 2025 | $3.57M | +107.9% | -19.6% |
| R&D Expense | June 30, 2022 | $1.69M | -69.0% | -5.4% |
| Operating Income | September 30, 2025 | -$1.99M | +11.8% | +20.3% |
| Gross Profit | September 30, 2024 | $547.0K | +892.8% | +1239.6% |
| Shares Outstanding | September 30, 2025 | 7.85M | +45.1% | +4.9% |
- Ernexa Therapeutics Inc. reported Total Revenue of $582.0 thousand for fiscal year 2024.
- Ernexa Therapeutics Inc. showed an increase of +755.9% in Total Revenue compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Revenue (ASC 606) of $5.80 million for fiscal year 2020.
- Ernexa Therapeutics Inc. showed a decrease of -70.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Net Income of -$14.08 million for fiscal year 2025.
- Ernexa Therapeutics Inc. showed an increase of +68.4% in Net Income compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Diluted EPS of $2.24 per share (loss) for fiscal year 2025.
- Ernexa Therapeutics Inc. showed an increase of +95.4% in Diluted EPS compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Total Assets of $5.83 million for fiscal year 2025.
- Ernexa Therapeutics Inc. showed an increase of +10.7% in Total Assets compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Cash and Equivalents of $1.73 million for fiscal year 2024.
- Ernexa Therapeutics Inc. showed a decrease of -77.2% in Cash and Equivalents compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Long-Term Debt of $532.0 thousand for fiscal year 2020.
- Ernexa Therapeutics Inc. reported Stockholders Equity of $2.40 million for fiscal year 2025.
- Ernexa Therapeutics Inc. showed an increase of +41.2% in Stockholders Equity compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Operating Income of -$9.32 million for fiscal year 2025.
- Ernexa Therapeutics Inc. showed an increase of +40.5% in Operating Income compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Gross Profit of $486.0 thousand for fiscal year 2024.
- Ernexa Therapeutics Inc. showed an increase of +389.3% in Gross Profit compared to the prior fiscal year.
- Ernexa Therapeutics Inc. reported Shares Outstanding of 7.85 million shares for fiscal year 2025.
- Ernexa Therapeutics Inc. showed an increase of +129.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: